Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Patterns of Survival in Patients with Aggressive B-Cell Lymphoma Treated with CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CART) As Second Versus Later Line of Therapy

Blood (2024) 144 (Supplement 1): 612.

https://doi.org/10.1182/blood-2024-202665

Published: 2024

Journal Articles

Mosunetuzumab with Response-Driven Lenalidomide Augmentation As First-Line Therapy for Symptomatic Follicular or Marginal Zone Lymphoma: Interim Analysis of a Multi-Center Phase 2 Study

Adam J. Olszewski, Matthew Matasar, Scott F Huntington, Thomas Ollila, Ari Pelcovits, Yun Kyoung Tiger, John L. Reagan, Anna Dorota Chorzalska, John Morgan, Makayla R Pardo, Jessica McMahon, Stephen Donnelly, Caylee Carmody, Jeannine Margolis, Charles Milrod, Patrycja M. Dubielecka

Blood (2024) 144 (Supplement 1): 1644.

https://doi.org/10.1182/blood-2024-193022

Published: 2024

Journal Articles

Efficacy, Toxicity, and Predictors of Outcomes with CD3-CD20 Bi-Specific Antibodies Post CAR T-Cell Failure for Aggressive B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 473.

https://doi.org/10.1182/blood-2024-201626

Published: 2024

Journal Articles

Evaluation of Outcomes and Toxicities of Commercial Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel (tisa-cel) for Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Real-World Evidence (RWE) from 10 US Academic Centers

Blood (2024) 144 (Supplement 1): 2377.

https://doi.org/10.1182/blood-2024-203753

Published: 2024

Journal Articles

Outcomes of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Extranodal (EN) B-Cell Non-Hodgkin Lymphoma (NHL): Results from a Multicenter Analysis

Blood (2024) 144 (Supplement 1): 3751.

https://doi.org/10.1182/blood-2024-209383

Published: 2024

Journal Articles

Circulating Biomarkers and CD8+ T-Cell Subpopulations Reveal Evolving Phases of Immune Response in Patients Receiving Mosunetuzumab for Previously Untreated B-Cell Lymphoma

Charles Milrod, Anna Dorota Chorzalska, John Morgan, Makayla R Pardo, Christina Raker, Thomas Ollila, Seo-Ho Lee, Ari Pelcovits, John L. Reagan, Jessica McMahon, Stephen Donnelly, Caylee Carmody, Jeannine Margolis, Matthew Matasar, Scott F Huntington, Patrycja M. Dubielecka, Adam J. Olszewski

Blood (2024) 144 (Supplement 1): 1614.

https://doi.org/10.1182/blood-2024-193023

Published: 2024

Journal Articles

Clinical Outcomes of Transformed Follicular Lymphoma with CAR T-Cell Therapy: A US Multicenter Real-World Analysis

Blood (2024) 144 (Supplement 1): 525.

https://doi.org/10.1182/blood-2024-212106

Published: 2024

Journal Articles

Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort

Juan Pablo Alderuccio, Jahanzaib Khwaja, Sunwoo Han, Paola Ghione, Imran A. Nizamuddin, Aditi Saha, Ning Dong, Yucai Wang, Hua-Jay J Cherng, Seda S. Tolu, Nina Wagner-Johnston, Adam J. Olszewski, Natalie Grover, Jean L. Koff, Amrita Desai, Praveen Ramakrishnan Geethakumari, Tamara K Moyo, Jose Sandoval-Sus, Narendranath Epperla, Danielle S Wallace, Manali Kamdar, Alexey Danilov, Han W. Tun, Javier Munoz, Mayur S. Narkhede, Joanna M. Rhodes, Anca Prica, Andrea Kuhnl, Adrian Maraj, Jessica Okosun, Jeffery Smith, Wendy Osborne, Victoria Calvert, Dima el-Sharkawi, Ammar Hilali, Graham P. Collins, Kim Linton, Nagah Elmusharaf, Anna Santarsieri, Farheen Karim, Thomas Ollila, Sarah Monick, Iris Margalit Trutzer, Nilanjan Ghosh, Jones Can, Amy Ayers, Jacopo Calabrese De Feo, John Sharp, Rachel Treitman, Avyakta Kallam, Izel Okcu, Vismay Deshani, Firas Baidoun, Chathuri Abeyakoon, William Hann, Aisling Barrett, Brad Kahl, Julio C. Chavez, Kate Cwynarski

Blood (2024) 144 (Supplement 1): 571.

https://doi.org/10.1182/blood-2024-199781

Published: 2024

Journal Articles

Trial in Progress - Alliance A051901 - Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed By Lenalidomide and Nivolumab Maintenance in Primary Central Nervous System Lymphoma (PCNSL)

Alvaro J Alencar, Olivia Bobek, Neha Mehta-Shah, Narendranath Epperla, Christine Lu-Emerson, Sarah C. Rutherford, Adam J. Olszewski, Thomas Ollila, Samuel Singer, Travis Dockter, Susan M. Geyer, Lori Rosenstein, Macarena De La Fuente, Eric D. Hsi, Shira N. Dinner, James L. Rubenstein, Nancy L. Bartlett, John P. Leonard

Blood (2024) 144 (Supplement 1): 4502.4.

https://doi.org/10.1182/blood-2024-209238

Published: 2024

Journal Articles

Alterations in Immune Cell Composition during First-Line Therapy with Mosunetuzumab for Follicular or Marginal Zone Lymphoma

Adam J Olszewski, Thomas Ollila, Ari Pelcovits, Anna Dorota Chorzalska, John Morgan, Jessica McMahon, Stephen Donnelly, Scott F. Huntington, Matthew Matasar, John L. Reagan, Charles Milrod, Patrycja M. Dubielecka

Blood (2023) 142 (Supplement 1): 1651.

https://doi.org/10.1182/blood-2023-181418

Published: 2023

Journal Articles

Correlation between PFS and OS in FL: Implications for Clinical Trial Endpoint Selection

Charles Milrod, Kang Woo Kim, Thomas Ollila, Adam J Olszewski, Ari Pelcovits

Blood (2023) 142 (Supplement 1): 4395.

https://doi.org/10.1182/blood-2023-177626

Published: 2023

Journal Articles

Exploration of Language As a Barrier to the Assessment and Management of CAR T-Cell Therapy Associated Toxicities

Blood (2023) 142 (Supplement 1): 2407.

https://doi.org/10.1182/blood-2023-183041

Published: 2023

Journal Articles

A Multicenter Study Analyzing Survival and Prognostic Factors in Patients with Leukemic Phase Follicular Lymphoma

Asaad Trabolsi, Narendranath Epperla, Kaitlin Annunzio, Dan Morgenstern Kaplan, Peter Doukas, Frederique St-Pierre, Brittany McCall, Lindsey Fitzgerald, Sunwoo Han, Isildinha M. Reis, Jennifer Rose Chapman-Fredricks, Khaled Alhamad, Thomas Ollila, Reem Karmali, Izidore S. Lossos, Juan Pablo Alderuccio

Blood (2023) 142 (Supplement 1): 3770.

https://doi.org/10.1182/blood-2023-173905

Published: 2023

Journal Articles

Immune Reconstitution and Infection Patterns Following CAR T-Cell Therapy in Patients with Aggressive Lymphoma

Blood (2023) 142 (Supplement 1): 1738.

https://doi.org/10.1182/blood-2023-183011

Published: 2023

Journal Articles

Marrow Hypocellularity, but Not Residual Blast Count, Is Prognostic on Day-14 Assessment in Acute Myeloid Leukemia

Thomas Ollila, MD, Adam J Olszewski, MD, Peter J. Quesenberry, MD, Matthew I. Quesenberry, MD, James Butera, MD, John L. Reagan, MD

Blood (2017) 130 (Supplement 1): 1428.

https://doi.org/10.1182/blood.V130.Suppl_1.1428.1428

Published: 2017

Journal Articles

Survival of Patients with Del(5q) Syndrome in the Lenalidomide Era

John L Reagan, MD, Thomas Ollila, MD, Patrycja M Dubielecka, PhD, Adam J Olszewski, MD

Blood (2016) 128 (22): 1994.

https://doi.org/10.1182/blood.V128.22.1994.1994

Published: 2016

Journal Articles

The Role of Day 14 Bone Marrow Analysis in Determining Leukemia Free Survival and Overall Survival

Thomas Ollila, MD, John L Reagan, MD, Jorge J Castillo, MD, James N Butera, MD, Eric S Winer, MD, Michael S Cardin, RPh

Blood (2015) 126 (23): 4974.

https://doi.org/10.1182/blood.V126.23.4974.4974

Published: 2015

NARROW

Patterns of Survival in Patients with Aggressive B-Cell Lymphoma Treated with CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CART) As Second Versus Later Line of Therapy

Mosunetuzumab with Response-Driven Lenalidomide Augmentation As First-Line Therapy for Symptomatic Follicular or Marginal Zone Lymphoma: Interim Analysis of a Multi-Center Phase 2 Study

Efficacy, Toxicity, and Predictors of Outcomes with CD3-CD20 Bi-Specific Antibodies Post CAR T-Cell Failure for Aggressive B-Cell Lymphoma

Evaluation of Outcomes and Toxicities of Commercial Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel (tisa-cel) for Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Real-World Evidence (RWE) from 10 US Academic Centers

Outcomes of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Extranodal (EN) B-Cell Non-Hodgkin Lymphoma (NHL): Results from a Multicenter Analysis

Circulating Biomarkers and CD8+ T-Cell Subpopulations Reveal Evolving Phases of Immune Response in Patients Receiving Mosunetuzumab for Previously Untreated B-Cell Lymphoma

Clinical Outcomes of Transformed Follicular Lymphoma with CAR T-Cell Therapy: A US Multicenter Real-World Analysis

Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort

Trial in Progress - Alliance A051901 - Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed By Lenalidomide and Nivolumab Maintenance in Primary Central Nervous System Lymphoma (PCNSL)

Alterations in Immune Cell Composition during First-Line Therapy with Mosunetuzumab for Follicular or Marginal Zone Lymphoma

Correlation between PFS and OS in FL: Implications for Clinical Trial Endpoint Selection

Exploration of Language As a Barrier to the Assessment and Management of CAR T-Cell Therapy Associated Toxicities

A Multicenter Study Analyzing Survival and Prognostic Factors in Patients with Leukemic Phase Follicular Lymphoma

Immune Reconstitution and Infection Patterns Following CAR T-Cell Therapy in Patients with Aggressive Lymphoma

Marrow Hypocellularity, but Not Residual Blast Count, Is Prognostic on Day-14 Assessment in Acute Myeloid Leukemia

Survival of Patients with Del(5q) Syndrome in the Lenalidomide Era

The Role of Day 14 Bone Marrow Analysis in Determining Leukemia Free Survival and Overall Survival

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only